Published in Nat Commun on March 18, 2014
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents. Dalton Trans (2015) 0.82
Single-molecule kinetics and footprinting of DNA bis-intercalation: the paradigmatic case of Thiocoraline. Nucleic Acids Res (2015) 0.81
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes. Dalton Trans (2016) 0.78
Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies. ChemMedChem (2015) 0.78
Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat Commun (2017) 0.78
Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands. Eur J Inorg Chem (2015) 0.77
Fingerprinting the junctions of RNA structure by an open-paddlewheel diruthenium compound. RNA (2016) 0.77
A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget (2016) 0.76
Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents. Nucleic Acids Res (2015) 0.76
Inhibition of cancer cell growth by ruthenium complexes. J Transl Med (2016) 0.75
The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects. Int J Mol Sci (2017) 0.75
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev (2017) 0.75
Visualization of metallodrugs in single cells by secondary ion mass spectrometry imaging. J Biol Inorg Chem (2017) 0.75
In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia. Chem Sci (2015) 0.75
Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol (1980) 287.68
Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins (2006) 22.80
The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr (2005) 19.21
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol (2002) 8.42
Refinement of the AMBER force field for nucleic acids: improving the description of alpha/gamma conformers. Biophys J (2007) 7.99
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J Phys Chem B (2008) 4.68
Direct cellular responses to platinum-induced DNA damage. Chem Rev (2007) 3.42
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
DNA stretching and extreme kinking in the nucleosome core. J Mol Biol (2007) 1.87
Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem (2001) 1.61
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer (2002) 1.45
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Nucleosome structural studies. Curr Opin Struct Biol (2010) 1.32
DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry (2003) 1.25
The mechanics behind DNA sequence-dependent properties of the nucleosome. Nucleic Acids Res (2012) 1.23
Site selectivity of platinum anticancer therapeutics. Nat Chem Biol (2007) 1.14
DNA stretching in the nucleosome facilitates alkylation by an intercalating antitumour agent. Nucleic Acids Res (2009) 1.10
Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA binding proteins and repair. Relationship to cytotoxicity. Chem Biol (2005) 0.98
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem (2010) 0.96
Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton Trans (2011) 0.95
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chemistry (2011) 0.92
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics (2011) 0.91
The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta (2002) 0.91
Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem (2011) 0.89
Chromatin - a new, old drug target? Chem Biol Drug Des (2008) 0.85
DNA structural distortions induced by ruthenium-arene anticancer compounds. J Am Chem Soc (2008) 0.85
Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation. Nucleic Acids Res (2011) 0.83
Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)]. J Inorg Biochem (2008) 0.82
Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. Metallomics (2012) 0.82
Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells. Anal Biochem (2009) 0.80
The Hummel-Dreyer method: impact in pharmacology. Biomed Chromatogr (2004) 0.80
Direct synthesis of formic acid from carbon dioxide by hydrogenation in acidic media. Nat Commun (2014) 1.00
Robust High-performance Dye-sensitized Solar Cells Based on Ionic Liquid-sulfolane Composite Electrolytes. Sci Rep (2015) 0.79
NanoSIMS analysis of an isotopically labelled organometallic ruthenium(ii) drug to probe its distribution and state in vitro. Chem Commun (Camb) (2015) 0.78
Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat Commun (2017) 0.78
Palladium-catalyzed aminocarbonylation of alkynes to succinimides. J Org Chem (2014) 0.77
Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds. Inorg Chem (2016) 0.76
Structural and Energetic Properties of Organometallic Ruthenium(II) Diamine Anticancer Compounds and Their Interaction with Nucleobases. J Chem Theory Comput (2007) 0.75
Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates. J Inorg Biochem (2017) 0.75
Correction: NanoSIMS analysis of an isotopically labelled organometallic ruthenium(ii) drug to probe its distribution and state in vitro. Chem Commun (Camb) (2015) 0.75